%0 Journal Article
%A Couñago, F
%A Rodriguez de Dios, N
%A Montemuiño, S
%A Jové-Teixidó, J
%A Martin, M
%A Calvo-Crespo, P
%A López-Mata, M
%A Samper-Ots, M P
%A López-Guerra, J L
%A García-Cañibano, T
%A Díaz-Díaz, V
%A de Ingunza-Barón, L
%A Murcia-Mejía, M
%A Alcántara, P
%A Corona, J
%A Puertas, M M
%A Chust, M
%A Couselo, M L
%A Del Cerro, E
%A Moradiellos, J
%A Amor, S
%A Varela, A
%A Thuissard, I J
%A Sanz-Rosa, D
%A Taboada, B
%T Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society).
%D 2018
%U http://hdl.handle.net/10668/12269
%X The role of surgery in stage IIIA-N2 non-small cell lung cancer (NSCLC) is an actively debated in oncology. To evaluate the value of surgery in this patient population, we conducted a multi-institutional retrospective study comparing neoadjuvant chemoradiotherapy or chemotherapy plus surgery (CRTS) to definitive chemoradiotherapy (dCRT). A total of 247 patients with potentially resectable stage T1-T3N2M0 NSCLC treated with either CRTS or dCRT between January 2005 and December 2014 at 15 hospitals in Spain were identified. A centralized review was performed to ensure resectability. A propensity score matched analysis was carried out to balance patient and tumor characteristics (n = 78 per group). Of the 247 patients, 118 were treated with CRTS and 129 with dCRT. In the CRTS group, 62 patients (52.5%) received neoadjuvant CRT and 56 (47.4%) neoadjuvant chemotherapy. Surgery consisted of either lobectomy (97 patients; 82.2%) or pneumonectomy (21 patients; 17.8%). In the matched samples, median overall survival (OS; 56 vs 29 months, log-rank p = .002) and progression-free survival (PFS; 46 vs 15 months, log-rank p  The findings reported here indicate that neoadjuvant chemotherapy or chemoradiotherapy followed by surgery (preferably lobectomy) yields better OS and PFS than definitive chemoradiotherapy in patients with resectable stage IIIA-N2 NSCLC.
%K Chemoradiation
%K NSCLC
%K Neoadjuvant treatment
%K Surgery
%K stage IIIA
%~